Heat shock protein 90

Heat shock protein 90
Tirkfl at English Wikipedia · Public domain · source
Name	Heat shock protein 90
Organisms	Eukaryotes, Bacteria

Heat shock protein 90 is a highly conserved molecular chaperone that participates in folding, stabilization, and activation of a wide range of client proteins across eukaryotic and prokaryotic species. Discovered in heat-shock studies influenced by work at Cold Spring Harbor Laboratory, Rockefeller University, and Max Planck Society laboratories, HSP90 has been studied in contexts from basic cell biology at Harvard University to translational oncology at National Cancer Institute and pharmaceutical development at Pfizer and Novartis. It integrates signals from signaling networks studied at Massachusetts Institute of Technology and Stanford University and is central to proteostasis projects at institutions such as European Molecular Biology Laboratory.

Structure and Isoforms

HSP90 proteins are typically ~700–750 amino acids in eukaryotes and adopt a three-domain architecture consisting of an N-terminal ATP-binding domain, a charged middle domain, and a C-terminal dimerization domain; structural insights derive from crystallography efforts at European Synchrotron Radiation Facility and cryo-EM at California Institute of Technology. Major cytosolic isoforms in vertebrates include HSP90AA1 and HSP90AB1, while organelle-specific paralogs include endoplasmic reticulum-localized GRP94 (encoded by HSP90B1) and mitochondrial TRAP1; isoform diversity was characterized in comparative genomics projects at Sanger Institute and Broad Institute. Bacterial homologs such as HtpG reveal conserved ATPase motifs, informed by structural studies at Max Planck Institute for Biochemistry and functional assays developed at University of Oxford. Post-translational modification sites—phosphorylation, acetylation, SUMOylation—cluster in the charged linker and C-terminal regions, with site mapping performed by mass spectrometry groups at University of California, San Diego and EMBL-EBI.

Function and Mechanism of Action

HSP90 functions as an ATP-dependent chaperone that undergoes conformational cycles regulated by nucleotide binding and hydrolysis; mechanistic models come from single-molecule work at University of Chicago and biochemical kinetics at Johns Hopkins University. It stabilizes client proteins involved in signal transduction and cell cycle control—clients identified in proteomics screens at Dana-Farber Cancer Institute and Scripps Research—preventing aggregation and promoting maturation in concert with co-chaperones such as CDC37, AHA1, and p23, whose roles were elucidated in collaborations between Yale University and University of Cambridge. The HSP90 ATPase cycle is coupled to large-scale domain movements observed in studies by teams at ETH Zurich and University of Tokyo, and its conformational plasticity facilitates binding and release of structurally diverse clients characterized in interactome maps from Cold Spring Harbor Laboratory.

Regulation and Expression

Expression of HSP90 isoforms is regulated transcriptionally and post-transcriptionally by factors studied at Howard Hughes Medical Institute laboratories, including heat shock factor 1 (HSF1), whose activation was detailed in work at University of California, San Francisco and Imperial College London. Stress-responsive upregulation occurs in paradigms developed at National Institutes of Health and heat shock assays used at University of Geneva, while constitutive expression of certain isoforms is maintained via promoter analyses performed at Karolinska Institute and Yale School of Medicine. MicroRNA-mediated control and mRNA stability mechanisms were described by groups at Cold Spring Harbor Laboratory and Paul Ehrlich Institute. Cellular localization is regulated by organelle-targeting sequences and chaperone networks studied at Weizmann Institute of Science and McGill University.

Role in Cellular Stress and Disease

HSP90 plays central roles in the cellular stress response, protecting proteomes during thermal, oxidative, and hypoxic insults studied in models at Princeton University and University of California, Berkeley. Dysregulation and exploitation of HSP90 are implicated in cancer biology investigations at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, where stabilization of oncogenic kinases and transcription factors contributes to tumor progression. Neurodegenerative disease links—through modulation of aggregation-prone proteins—have been explored at University College London and Hopkins Center for Neurodegeneration and Repair, while infectious disease studies at London School of Hygiene & Tropical Medicine and Pasteur Institute examine pathogen HSP90 homologs as virulence factors. HSP90’s involvement in autoimmune and inflammatory disorders was probed in clinical studies at Mayo Clinic and Cleveland Clinic.

Interactions and Client Proteins

HSP90 interacts with a cohort of co-chaperones and client proteins forming dynamic complexes characterized by affinity proteomics at Stanford School of Medicine and University of Pennsylvania. Canonical clients include steroid hormone receptors (studied at University of Michigan), receptor tyrosine kinases such as EGFR and HER2 (characterized at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute), serine/threonine kinases including AKT and Cdk4 (investigated at Cold Spring Harbor Laboratory and Scripps Research), and transcription factors such as HIF-1α and p53 (studied at Fred Hutchinson Cancer Research Center and Institute Pasteur). Co-chaperones CDC37, Hop/STI1, and FKBP51 modulate client specificity and were defined in biochemical screens at University of Basel and University of Edinburgh. Large-scale interaction maps assembled by consortia at European Bioinformatics Institute and ProteomeXchange reveal context-dependent client repertoires across cell types.

Inhibitors and Therapeutic Targeting

HSP90 has been targeted pharmacologically by natural products and synthetic inhibitors developed at industrial and academic centers including GlaxoSmithKline, AstraZeneca, and Novartis; notable scaffolds include geldanamycin and radicicol derivatives, and ATP-competitive small molecules whose binding modes were elucidated at Roche structural biology labs. Clinical trials testing HSP90 inhibitors were coordinated through networks including National Cancer Institute and regulatory assessments at European Medicines Agency and U.S. Food and Drug Administration. Resistance mechanisms involving heat shock response induction and compensatory chaperones were characterized by research teams at Memorial Sloan Kettering Cancer Center and Cold Spring Harbor Laboratory, guiding combination strategies with kinase inhibitors and immune therapies explored at Johns Hopkins University and University of Oxford. Biomarker development and pharmacodynamic assays originated from collaborations among Fred Hutchinson Cancer Research Center, Translational Genomics Research Institute, and industry partners.

Category:Chaperone proteins